243 related articles for article (PubMed ID: 19177197)
1. Aberrant promoter methylation of SPARC in ovarian cancer.
Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
[TBL] [Abstract][Full Text] [Related]
2. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
Cheetham S; Tang MJ; Mesak F; Kennecke H; Owen D; Tai IT
Br J Cancer; 2008 Jun; 98(11):1810-9. PubMed ID: 18458674
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer.
Chen ZY; Zhang JL; Yao HX; Wang PY; Zhu J; Wang W; Wang X; Wan YL; Chen SW; Chen GW; Liu YC
Sci Rep; 2014 Dec; 4():7035. PubMed ID: 25516351
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
6. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers.
Yang E; Kang HJ; Koh KH; Rhee H; Kim NK; Kim H
Int J Cancer; 2007 Aug; 121(3):567-75. PubMed ID: 17397030
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.
Zhang Y; Yang B; Du Z; Bai T; Gao YT; Wang YJ; Lou C; Wang FM; Bai Y
World J Gastroenterol; 2012 May; 18(17):2043-52. PubMed ID: 22563191
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
9. [Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism].
Li M; Huang ZJ; Dong WH; Li XY; Wang XY; He XH; Wang H; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):408-12. PubMed ID: 16831366
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
11. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of secreted protein acidic and rich in cysteine gene and its significance in gastric cancer.
Shao S; Zhou NM; Dai DQ
World J Gastroenterol; 2019 Dec; 25(46):6713-6727. PubMed ID: 31857774
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.
Sakuma M; Akahira J; Ito K; Niikura H; Moriya T; Okamura K; Sasano H; Yaegashi N
Cancer Sci; 2007 Mar; 98(3):380-6. PubMed ID: 17270028
[TBL] [Abstract][Full Text] [Related]
16. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD; Rivenbark AG; Jones WD; Coleman WB
Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the PTEN gene in ovarian cancer cell lines.
Schöndorf T; Ebert MP; Hoffmann J; Becker M; Moser N; Pur S; Göhring UJ; Weisshaar MP
Cancer Lett; 2004 Apr; 207(2):215-20. PubMed ID: 15072831
[TBL] [Abstract][Full Text] [Related]
18. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
19. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
Takada T; Yagi Y; Maekita T; Imura M; Nakagawa S; Tsao SW; Miyamoto K; Yoshino O; Yasugi T; Taketani Y; Ushijima T
Cancer Sci; 2004 Sep; 95(9):741-4. PubMed ID: 15471560
[TBL] [Abstract][Full Text] [Related]
20. [Reversal effect of 5-aza-2-deoxycytidine on the maternally expressed gene 3 promoter hypermethylation and its inhibitory effect on the proliferation of epithelial ovarian cancer cells].
Li J; Zhou D; Wang Z; Tan L; Zhou Y; Li J; Sheng X
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):324-9. PubMed ID: 26463020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
